Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Inhibrx Biosciences, Inc
NiKang Therapeutics, Inc.
Revolution Medicines, Inc.
Stanford University
University Health Network, Toronto
University Medical Center Groningen
Revolution Medicines, Inc.
Syndax Pharmaceuticals
Syndax Pharmaceuticals
University Hospital, Bordeaux
Cedars-Sinai Medical Center
Dendreon
UroGen Pharma Ltd.